Attached files
| file | filename |
|---|---|
| EX-32 - EXHIBIT 32 - ACURA PHARMACEUTICALS, INC | tv490022_ex32.htm |
| EX-31.2 - EXHIBIT 31.2 - ACURA PHARMACEUTICALS, INC | tv490022_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - ACURA PHARMACEUTICALS, INC | tv490022_ex31-1.htm |
| EX-10.34 - EXHIBIT 10.34 - ACURA PHARMACEUTICALS, INC | tv490022_ex10-34.htm |
| 10-K - FORM 10-K - ACURA PHARMACEUTICALS, INC | tv490022_10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Acura Pharmaceuticals, Inc.
Palatine, Illinois
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-221645, 333-213017, 333-195612, 333-151653, 333-151620, 333-133172, 333-123615, 333-63288, and 33-98396), and on Form S-3 (Nos. 333-210039 and 333-146416) of Acura Pharmaceuticals, Inc. of our report dated June 7, 2018, relating to the consolidated financial statements, which appear in this Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
| /s/ BDO USA, LLP | |
| Chicago, Illinois | |
June 7, 2018 | |